LAB Q4 2020 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q4 2020 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$45M+37.5% YoY

Gross Profit

$26M58.8% margin

Operating Income

-$17M-37.9% margin

Net Income

-$18M-40.4% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+11.9%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$14M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$325M

Total Liabilities

$186M

Stockholders' Equity

$139M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$32M	+37.5%
Gross Profit	$26M	$18M	+46.6%
Operating Income	-$17M	-$9M	-84.1%
Net Income	-$18M	-$13M	-42.1%

Revenue Segments

Product

$34M77%

Service

$6M14%

Collaboration Revenue

$3M6%

Product and Service, Other

$1M3%

Geographic Segments

Americas

$22M50%

EMEA

$14M32%

Asia Pacific

$8M18%